CN115989235A - 使用氨基酸化合物治疗呼吸系统疾病的方法 - Google Patents
使用氨基酸化合物治疗呼吸系统疾病的方法 Download PDFInfo
- Publication number
- CN115989235A CN115989235A CN202180048580.XA CN202180048580A CN115989235A CN 115989235 A CN115989235 A CN 115989235A CN 202180048580 A CN202180048580 A CN 202180048580A CN 115989235 A CN115989235 A CN 115989235A
- Authority
- CN
- China
- Prior art keywords
- optionally substituted
- deuterium
- compound
- halogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 394
- -1 amino acid compounds Chemical class 0.000 title claims description 139
- 208000023504 respiratory system disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 958
- 150000003839 salts Chemical class 0.000 claims abstract description 261
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 73
- 102000006495 integrins Human genes 0.000 claims abstract description 70
- 108010044426 integrins Proteins 0.000 claims abstract description 70
- 244000052769 pathogen Species 0.000 claims abstract description 66
- 208000014674 injury Diseases 0.000 claims abstract description 43
- 230000008733 trauma Effects 0.000 claims abstract description 38
- 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 claims abstract description 32
- 208000005069 pulmonary fibrosis Diseases 0.000 claims abstract description 26
- 208000035475 disorder Diseases 0.000 claims abstract description 23
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 19
- 206010033645 Pancreatitis Diseases 0.000 claims abstract description 12
- 230000035939 shock Effects 0.000 claims abstract description 11
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 376
- 229910052805 deuterium Inorganic materials 0.000 claims description 376
- 229910052736 halogen Inorganic materials 0.000 claims description 282
- 150000002367 halogens Chemical class 0.000 claims description 228
- 125000004043 oxo group Chemical group O=* 0.000 claims description 171
- 229910052739 hydrogen Inorganic materials 0.000 claims description 167
- 239000001257 hydrogen Substances 0.000 claims description 138
- 125000003118 aryl group Chemical group 0.000 claims description 103
- 125000000623 heterocyclic group Chemical group 0.000 claims description 102
- 125000000217 alkyl group Chemical group 0.000 claims description 86
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 86
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 84
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 84
- 125000001072 heteroaryl group Chemical group 0.000 claims description 81
- 125000003545 alkoxy group Chemical group 0.000 claims description 71
- 125000004432 carbon atom Chemical group C* 0.000 claims description 69
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 68
- 229910052799 carbon Inorganic materials 0.000 claims description 68
- 125000001188 haloalkyl group Chemical group 0.000 claims description 68
- 230000001717 pathogenic effect Effects 0.000 claims description 64
- 125000005843 halogen group Chemical group 0.000 claims description 63
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 57
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 57
- 150000002431 hydrogen Chemical class 0.000 claims description 56
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 53
- 229910052731 fluorine Inorganic materials 0.000 claims description 53
- 239000011737 fluorine Substances 0.000 claims description 52
- 201000010099 disease Diseases 0.000 claims description 50
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 49
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 49
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 45
- 125000001153 fluoro group Chemical group F* 0.000 claims description 43
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 41
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 41
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 38
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims description 34
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 31
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 30
- 125000004429 atom Chemical group 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 230000002018 overexpression Effects 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 125000004076 pyridyl group Chemical group 0.000 claims description 23
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 22
- 206010016654 Fibrosis Diseases 0.000 claims description 21
- 125000004431 deuterium atom Chemical group 0.000 claims description 21
- 230000004761 fibrosis Effects 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 20
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 19
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 17
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 17
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 15
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 14
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 14
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 14
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 14
- 230000003176 fibrotic effect Effects 0.000 claims description 14
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 13
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 13
- 241001678559 COVID-19 virus Species 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 12
- 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 claims description 12
- 206010035664 Pneumonia Diseases 0.000 claims description 11
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 11
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 11
- 230000005855 radiation Effects 0.000 claims description 10
- 208000025721 COVID-19 Diseases 0.000 claims description 9
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims description 8
- 241000711573 Coronaviridae Species 0.000 claims description 8
- 208000011231 Crohn disease Diseases 0.000 claims description 8
- 206010039710 Scleroderma Diseases 0.000 claims description 8
- 208000020832 chronic kidney disease Diseases 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 241000712461 unidentified influenza virus Species 0.000 claims description 8
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 7
- 208000024985 Alport syndrome Diseases 0.000 claims description 7
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 7
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims description 7
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 7
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 7
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 7
- 201000005271 biliary atresia Diseases 0.000 claims description 7
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 7
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims description 7
- 208000003215 hereditary nephritis Diseases 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 239000002243 precursor Substances 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 241000712431 Influenza A virus Species 0.000 claims description 6
- 241000283966 Pholidota <mammal> Species 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 6
- 206010069351 acute lung injury Diseases 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 244000052637 human pathogen Species 0.000 claims description 5
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 5
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 241000283984 Rodentia Species 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 125000005347 halocycloalkyl group Chemical group 0.000 claims description 4
- 210000002216 heart Anatomy 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 4
- 241000272525 Anas platyrhynchos Species 0.000 claims description 3
- 241000272814 Anser sp. Species 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 3
- 206010061688 Barotrauma Diseases 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- 241000282465 Canis Species 0.000 claims description 3
- 101000966429 Chlamydomonas reinhardtii Dynein, 70 kDa intermediate chain, flagellar outer arm Proteins 0.000 claims description 3
- 208000005189 Embolism Diseases 0.000 claims description 3
- 241000282324 Felis Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 241000287828 Gallus gallus Species 0.000 claims description 3
- 206010022773 Intracranial pressure increased Diseases 0.000 claims description 3
- 241000270322 Lepidosauria Species 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 3
- 210000000232 gallbladder Anatomy 0.000 claims description 3
- 210000002429 large intestine Anatomy 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 3
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 claims description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 210000002460 smooth muscle Anatomy 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 210000001550 testis Anatomy 0.000 claims description 3
- 210000003708 urethra Anatomy 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 210000005166 vasculature Anatomy 0.000 claims description 3
- VFZYCYBBIMIWOZ-UHFFFAOYSA-N 2-ethoxy-2-hydroxy-2-methoxyacetamide Chemical compound OC(C(=O)N)(OCC)OC VFZYCYBBIMIWOZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 2
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 claims description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims description 2
- HBGXFJGNUSQCKP-UHFFFAOYSA-N n-methyl-1-phenoxymethanamine Chemical compound CNCOC1=CC=CC=C1 HBGXFJGNUSQCKP-UHFFFAOYSA-N 0.000 claims description 2
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- AUPMTUXGMWHXRT-VWLOTQADSA-N (2S)-2-[(2-methylpyrazolo[4,3-d]pyrimidin-7-yl)amino]-4-[2-phenoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound CN1N=C2C(N=CN=C2N[C@H](C(=O)O)CCN(CCCCC2=NC=3NCCCC=3C=C2)CCOC2=CC=CC=C2)=C1 AUPMTUXGMWHXRT-VWLOTQADSA-N 0.000 claims 1
- WTPBTCDPVXXKAZ-LJAQVGFWSA-N (2S)-2-[(7-fluoro-2-methylquinazolin-4-yl)amino]-4-[2-(4-fluorophenoxy)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound FC1=CC=C2C(=NC(=NC2=C1)C)N[C@H](C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC1=CC=C(C=C1)F WTPBTCDPVXXKAZ-LJAQVGFWSA-N 0.000 claims 1
- YWIXAKYDQQOJLI-LJAQVGFWSA-N (2S)-4-[2-(3,5-difluorophenoxy)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound FC=1C=C(OCCN(CC[C@@H](C(=O)O)NC2=NC=NC3=CC=CC=C23)CCCCC2=NC=3NCCCC=3C=C2)C=C(C=1)F YWIXAKYDQQOJLI-LJAQVGFWSA-N 0.000 claims 1
- SLNKBRJNJVIOMK-VWLOTQADSA-N (2S)-4-[2-(4-fluorophenoxy)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(2-methylpyrazolo[4,3-d]pyrimidin-7-yl)amino]butanoic acid Chemical compound FC1=CC=C(OCCN(CC[C@@H](C(=O)O)NC=2C=3C(N=CN=2)=CN(N=3)C)CCCCC2=NC=3NCCCC=3C=C2)C=C1 SLNKBRJNJVIOMK-VWLOTQADSA-N 0.000 claims 1
- ZOONEWNJDYOTCN-QHCPKHFHSA-N (2S)-4-[2-hydroxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound OCCN(CC[C@@H](C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 ZOONEWNJDYOTCN-QHCPKHFHSA-N 0.000 claims 1
- CWOFQJBATWQSHL-DEOSSOPVSA-N (2S)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound COCCN(CCCCc1ccc2CCCNc2n1)CC[C@H](Nc1ncnc2ccccc12)C(O)=O CWOFQJBATWQSHL-DEOSSOPVSA-N 0.000 claims 1
- CNBMGCINRUYBSL-VWLOTQADSA-N (2S)-4-[2-phenoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)butanoic acid Chemical compound N1N=CC=2C1=NC=NC=2N[C@H](C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC1=CC=CC=C1 CNBMGCINRUYBSL-VWLOTQADSA-N 0.000 claims 1
- GPIRPBZZFNJFCB-QFIPXVFZSA-N (2S)-4-[3-fluoropropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(6-pyrazol-1-ylpyrimidin-4-yl)amino]butanoic acid Chemical compound N1(N=CC=C1)C1=CC(=NC=N1)N[C@H](C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCCF GPIRPBZZFNJFCB-QFIPXVFZSA-N 0.000 claims 1
- NVLYXBFFOXEVJK-IRLDBZIGSA-N (2S)-4-[[(2S)-3-fluoro-2-methoxypropyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(thieno[2,3-d]pyrimidin-4-ylamino)butanoic acid Chemical compound FC[C@H](CN(CC[C@@H](C(=O)O)NC=1C2=C(N=CN=1)SC=C2)CCCCC1=NC=2NCCCC=2C=C1)OC NVLYXBFFOXEVJK-IRLDBZIGSA-N 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 17
- 239000003112 inhibitor Substances 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 description 149
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 48
- 239000000243 solution Substances 0.000 description 38
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 36
- 229910052722 tritium Inorganic materials 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- 239000012535 impurity Substances 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 21
- 239000012071 phase Substances 0.000 description 19
- 238000010898 silica gel chromatography Methods 0.000 description 19
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 18
- 239000000460 chlorine Substances 0.000 description 17
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- 125000003367 polycyclic group Chemical group 0.000 description 16
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 15
- 125000005842 heteroatom Chemical group 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- 239000001301 oxygen Chemical group 0.000 description 15
- 229910052760 oxygen Inorganic materials 0.000 description 15
- 125000004450 alkenylene group Chemical group 0.000 description 14
- 125000004419 alkynylene group Chemical group 0.000 description 14
- 125000000753 cycloalkyl group Chemical group 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 229910052717 sulfur Chemical group 0.000 description 13
- 239000011593 sulfur Chemical group 0.000 description 13
- 125000002947 alkylene group Chemical group 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 125000003342 alkenyl group Chemical group 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 10
- 125000000304 alkynyl group Chemical group 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 125000002993 cycloalkylene group Chemical group 0.000 description 9
- 239000003937 drug carrier Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- NETQOLVTQJGGOA-UHFFFAOYSA-N N-(2-methoxyethyl)-4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butan-1-amine Chemical compound COCCNCCCCC1=NC=2NCCCC=2C=C1 NETQOLVTQJGGOA-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- PGLWDUMYQCCUEN-BWKNWUBXSA-N (2S)-4-[[(2R)-2-methoxypropyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound C(C1=CC=CC=C1)OC(=O)N[C@H](C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)C[C@@H](C)OC PGLWDUMYQCCUEN-BWKNWUBXSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- GKFPWSKVKPWRBY-UHFFFAOYSA-N N-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]formamide Chemical compound N1=C(C=CC=2CCCNC1=2)CCCCNC=O GKFPWSKVKPWRBY-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 125000002015 acyclic group Chemical group 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- IAWFMNHHXQERPJ-IBGZPJMESA-N methyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-[methyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoate Chemical compound C(C)(C)(C)OC(=O)N[C@H](C(=O)OC)CCN(CCCCC1=NC=2NCCCC=2C=C1)C IAWFMNHHXQERPJ-IBGZPJMESA-N 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- LYUZTYWRMDWSDU-YWEHKCAJSA-N tert-butyl (2S)-4-[[(2R)-2-methoxypropyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(phenylmethoxycarbonylamino)butanoate Chemical compound C(C1=CC=CC=C1)OC(=O)N[C@H](C(=O)OC(C)(C)C)CCN(CCCCC1=NC=2NCCCC=2C=C1)C[C@@H](C)OC LYUZTYWRMDWSDU-YWEHKCAJSA-N 0.000 description 6
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical group C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 description 5
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- ZQVLGRRPQXPTQM-NQIIRXRSSA-N tert-butyl (2S)-2-amino-4-[[(2R)-2-methoxypropyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoate Chemical compound N[C@H](C(=O)OC(C)(C)C)CCN(CCCCC1=NC=2NCCCC=2C=C1)C[C@@H](C)OC ZQVLGRRPQXPTQM-NQIIRXRSSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 238000000844 transformation Methods 0.000 description 5
- GJMIPLJNDWSQNC-KNQAVFIVSA-N (2S)-4-[[(2R)-2-methoxypropyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(5-methylpyrimidin-2-yl)amino]butanoic acid Chemical compound CO[C@@H](CN(CC[C@@H](C(=O)O)NC1=NC=C(C=N1)C)CCCCC1=NC=2NCCCC=2C=C1)C GJMIPLJNDWSQNC-KNQAVFIVSA-N 0.000 description 4
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical group N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 4
- NXMFJCRMSDRXLD-UHFFFAOYSA-N 2-aminopyridine-3-carbaldehyde Chemical compound NC1=NC=CC=C1C=O NXMFJCRMSDRXLD-UHFFFAOYSA-N 0.000 description 4
- QFRQJEGTZVFEJQ-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butan-1-amine Chemical compound C1CCNC2=NC(CCCCN)=CC=C21 QFRQJEGTZVFEJQ-UHFFFAOYSA-N 0.000 description 4
- BREOKHDXONYFEN-UHFFFAOYSA-N 5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentanoic acid Chemical group C1CCNC2=NC(CCCCC(=O)O)=CC=C21 BREOKHDXONYFEN-UHFFFAOYSA-N 0.000 description 4
- NAFFOKWDDBUXEQ-UHFFFAOYSA-N 6-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)hexanoic acid Chemical group N1=C(C=CC=2CCCNC1=2)CCCCCC(=O)O NAFFOKWDDBUXEQ-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- FMHCGCMWHIRWMG-FQEVSTJZSA-N CN(CCCCC1=NC(NCCC2)=C2C=C1)CC[C@@H](C(O)=O)NC(C(C=CC=C1F)=C1Cl)=O Chemical compound CN(CCCCC1=NC(NCCC2)=C2C=C1)CC[C@@H](C(O)=O)NC(C(C=CC=C1F)=C1Cl)=O FMHCGCMWHIRWMG-FQEVSTJZSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- MKSNFWMWCXSXNC-UHFFFAOYSA-N N-cyclopropyl-4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butanamide Chemical compound C1(CC1)NC(CCCC1=NC=2NCCCC=2C=C1)=O MKSNFWMWCXSXNC-UHFFFAOYSA-N 0.000 description 4
- JCKULKKZNHHNRZ-UHFFFAOYSA-N N-methyl-4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butan-1-amine Chemical compound CNCCCCC1=NC=2NCCCC=2C=C1 JCKULKKZNHHNRZ-UHFFFAOYSA-N 0.000 description 4
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 125000000732 arylene group Chemical group 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- SVQMHAHLFODOPJ-SFHVURJKSA-N methyl (2S)-2-amino-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoate Chemical compound N[C@H](C(=O)OC)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC SVQMHAHLFODOPJ-SFHVURJKSA-N 0.000 description 4
- RSDYTQHHOKYMSH-INIZCTEOSA-N methyl (2S)-2-amino-4-[methyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoate Chemical compound N[C@H](C(=O)OC)CCN(CCCCC1=NC=2NCCCC=2C=C1)C RSDYTQHHOKYMSH-INIZCTEOSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- MDFBVAIXHWKHTF-RDGATRHJSA-N tert-butyl (2S)-4-[[(2R)-2-methoxypropyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(5-methylpyrimidin-2-yl)amino]butanoate Chemical compound CO[C@@H](CN(CC[C@@H](C(=O)OC(C)(C)C)NC1=NC=C(C=N1)C)CCCCC1=NC=2NCCCC=2C=C1)C MDFBVAIXHWKHTF-RDGATRHJSA-N 0.000 description 4
- 150000003512 tertiary amines Chemical group 0.000 description 4
- KPELUVFYFBYKOB-KRWDZBQOSA-N (2s)-3-(dibenzylamino)-2-fluoropropan-1-ol Chemical compound C=1C=CC=CC=1CN(C[C@H](F)CO)CC1=CC=CC=C1 KPELUVFYFBYKOB-KRWDZBQOSA-N 0.000 description 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 3
- IZOQMUVIDMLRDC-UHFFFAOYSA-M 6-oxoheptanoate Chemical compound CC(=O)CCCCC([O-])=O IZOQMUVIDMLRDC-UHFFFAOYSA-M 0.000 description 3
- OSAHCBHKCKPJGI-UHFFFAOYSA-M 7-oxooctanoate Chemical compound CC(=O)CCCCCC([O-])=O OSAHCBHKCKPJGI-UHFFFAOYSA-M 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- CYHARKQMMASXKZ-SANMLTNESA-N methyl (2S)-2-(isoquinolin-1-ylamino)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoate Chemical compound C1(=NC=CC2=CC=CC=C12)N[C@H](C(=O)OC)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC CYHARKQMMASXKZ-SANMLTNESA-N 0.000 description 3
- DSHBSDICLNVZQW-MHZLTWQESA-N methyl (2S)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinolin-4-ylamino)butanoate Chemical compound COCCN(CC[C@@H](C(=O)OC)NC1=CC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 DSHBSDICLNVZQW-MHZLTWQESA-N 0.000 description 3
- VAAGDABRDJFHHK-QGZVFWFLSA-N methyl (2r)-2-(dibenzylamino)-3-hydroxypropanoate Chemical compound C=1C=CC=CC=1CN([C@H](CO)C(=O)OC)CC1=CC=CC=C1 VAAGDABRDJFHHK-QGZVFWFLSA-N 0.000 description 3
- OBKSTEOVEUUBBH-KRWDZBQOSA-N methyl (2s)-3-(dibenzylamino)-2-fluoropropanoate Chemical compound C=1C=CC=CC=1CN(C[C@H](F)C(=O)OC)CC1=CC=CC=C1 OBKSTEOVEUUBBH-KRWDZBQOSA-N 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 125000003566 oxetanyl group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- ANPQRLIKWVTIMZ-UHFFFAOYSA-N tert-butyl 7-(4-ethoxy-4-oxobutyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxylate Chemical compound CCOC(=O)CCCC1=NC2=C(CCCN2C(=O)OC(C)(C)C)C=C1 ANPQRLIKWVTIMZ-UHFFFAOYSA-N 0.000 description 3
- KZXMKKSDVITCAY-UHFFFAOYSA-N tert-butyl 7-(4-hydroxybutyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxylate Chemical compound OCCCCC1=CC=C2CCCN(C2=N1)C(=O)OC(C)(C)C KZXMKKSDVITCAY-UHFFFAOYSA-N 0.000 description 3
- UKKDZRGPGFGAJF-UHFFFAOYSA-N tert-butyl 7-(4-oxobutyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCc2ccc(CCCC=O)nc12 UKKDZRGPGFGAJF-UHFFFAOYSA-N 0.000 description 3
- RKSOPLXZQNSWAS-UHFFFAOYSA-N tert-butyl bromide Chemical compound CC(C)(C)Br RKSOPLXZQNSWAS-UHFFFAOYSA-N 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- UDXPSGGWHXANSA-VWLOTQADSA-N (2S)-2-[(3-cyanopyrazin-2-yl)amino]-4-[2-(3,5-difluorophenoxy)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound C(#N)C=1C(=NC=CN=1)N[C@H](C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC1=CC(=CC(=C1)F)F UDXPSGGWHXANSA-VWLOTQADSA-N 0.000 description 2
- FPCXCUQISKJWBQ-NDEPHWFRSA-N (2S)-4-[2-(3,5-difluorophenoxy)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(1-methylindazol-3-yl)amino]butanoic acid Chemical compound FC=1C=C(OCCN(CC[C@@H](C(=O)O)NC2=NN(C3=CC=CC=C23)C)CCCCC2=NC=3NCCCC=3C=C2)C=C(C=1)F FPCXCUQISKJWBQ-NDEPHWFRSA-N 0.000 description 2
- CIGGJPDHCYAIBO-SFHVURJKSA-N (2S)-N,N-dibenzyl-2-fluoro-3-methoxypropan-1-amine Chemical compound C(C1=CC=CC=C1)N(C[C@@H](COC)F)CC1=CC=CC=C1 CIGGJPDHCYAIBO-SFHVURJKSA-N 0.000 description 2
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 2
- MCLXGVNIBMHMNS-UHFFFAOYSA-N 1-methylpyrazolo[3,4-d]pyrimidine Chemical group N1=CN=C2N(C)N=CC2=C1 MCLXGVNIBMHMNS-UHFFFAOYSA-N 0.000 description 2
- OVEITJSDGWRVLP-UHFFFAOYSA-N 2-(3,5-difluorophenoxy)ethanamine Chemical group NCCOC1=CC(F)=CC(F)=C1 OVEITJSDGWRVLP-UHFFFAOYSA-N 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- RNQDBLUYYSHGRP-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butanoic acid;hydrochloride Chemical compound Cl.C1CCNC2=NC(CCCC(=O)O)=CC=C21 RNQDBLUYYSHGRP-UHFFFAOYSA-N 0.000 description 2
- JYLBKMNTQSEPJM-UHFFFAOYSA-N 4-chloro-2-methyl-6-(trifluoromethyl)pyrimidine Chemical compound CC1=NC(Cl)=CC(C(F)(F)F)=N1 JYLBKMNTQSEPJM-UHFFFAOYSA-N 0.000 description 2
- HXWAAYFRMOCBJC-UHFFFAOYSA-N 5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentan-1-amine Chemical compound C1CCNC2=NC(CCCCCN)=CC=C21 HXWAAYFRMOCBJC-UHFFFAOYSA-N 0.000 description 2
- KNOOCZSLRGJYRK-UHFFFAOYSA-N 6-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)hexan-1-amine Chemical compound N1=C(C=CC=2CCCNC1=2)CCCCCCN KNOOCZSLRGJYRK-UHFFFAOYSA-N 0.000 description 2
- KSVRCMNYOXDBTE-UHFFFAOYSA-N CCOC(=O)CCCCCC1=NC2=C(CCCN2)C=C1 Chemical compound CCOC(=O)CCCCCC1=NC2=C(CCCN2)C=C1 KSVRCMNYOXDBTE-UHFFFAOYSA-N 0.000 description 2
- OEYWDKZNZBJNHQ-NRFANRHFSA-N CN(CCCCC1=NC(NCCC2)=C2C=C1)CC[C@@H](C(OC)=O)NC(C(C=CC=C1F)=C1Cl)=O Chemical compound CN(CCCCC1=NC(NCCC2)=C2C=C1)CC[C@@H](C(OC)=O)NC(C(C=CC=C1F)=C1Cl)=O OEYWDKZNZBJNHQ-NRFANRHFSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 101150065749 Churc1 gene Proteins 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000238367 Mya arenaria Species 0.000 description 2
- LSISVJVWVDDWRU-UHFFFAOYSA-N N-(2-methoxyethyl)-4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butanamide Chemical compound COCCNC(CCCC1=NC=2NCCCC=2C=C1)=O LSISVJVWVDDWRU-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100038239 Protein Churchill Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Chemical group 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000004980 cyclopropylene group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- SACNIGZYDTUHKB-UHFFFAOYSA-N ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C SACNIGZYDTUHKB-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 2
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 2
- CHYXYVKQGNVFAC-UHFFFAOYSA-N ethyl 5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentanoate Chemical compound C1CCNC2=NC(CCCCC(=O)OCC)=CC=C21 CHYXYVKQGNVFAC-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- OBJFDAFCHPCIBH-LPECGTQYSA-N methyl (2S)-2-amino-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoate trihydrochloride Chemical compound Cl.Cl.Cl.N[C@H](C(=O)OC)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC OBJFDAFCHPCIBH-LPECGTQYSA-N 0.000 description 2
- RUUSKKCUIOZBAR-NRFANRHFSA-N methyl (2S)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[2-methyl-6-(trifluoromethyl)pyrimidin-4-yl]amino]butanoate Chemical compound COCCN(CC[C@@H](C(=O)OC)NC1=NC(=NC(=C1)C(F)(F)F)C)CCCCC1=NC=2NCCCC=2C=C1 RUUSKKCUIOZBAR-NRFANRHFSA-N 0.000 description 2
- SNJLHLNFHWPITN-GJZUVCINSA-N methyl (2S)-4-[[(2R)-2-methoxypropyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(phenylmethoxycarbonylamino)butanoate Chemical compound C(C1=CC=CC=C1)OC(=O)N[C@H](C(=O)OC)CCN(CCCCC1=NC=2NCCCC=2C=C1)C[C@@H](C)OC SNJLHLNFHWPITN-GJZUVCINSA-N 0.000 description 2
- YRBARHABTATAFQ-ZETCQYMHSA-N methyl (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoate Chemical compound COC(=O)[C@H](CC=O)NC(=O)OC(C)(C)C YRBARHABTATAFQ-ZETCQYMHSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical group N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 description 2
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical group C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 2
- PAQYIEZTLSDLQO-UHFFFAOYSA-N pyrido[3,4-d]pyrimidine Chemical group N1=CN=C2C=NC=CC2=C1 PAQYIEZTLSDLQO-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- MDFBVAIXHWKHTF-DHLKQENFSA-N tert-butyl (2S)-4-[[(2S)-2-methoxypropyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(5-methylpyrimidin-2-yl)amino]butanoate Chemical compound CO[C@H](CN(CC[C@@H](C(=O)OC(C)(C)C)NC1=NC=C(C=N1)C)CCCCC1=NC=2NCCCC=2C=C1)C MDFBVAIXHWKHTF-DHLKQENFSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- GOCVRNFLAAZVOM-QAPCUYQASA-N (2S)-2-amino-4-[[(2R)-2-methoxypropyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound N[C@H](C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)C[C@@H](C)OC GOCVRNFLAAZVOM-QAPCUYQASA-N 0.000 description 1
- BHXJIJFQIQVXKR-BYPYZUCNSA-N (2S)-2-fluoro-3-methoxypropan-1-amine Chemical compound COC[C@@H](F)CN BHXJIJFQIQVXKR-BYPYZUCNSA-N 0.000 description 1
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 description 1
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- HRFUBWQYIAMTOD-UHFFFAOYSA-N 1,2,3,4-tetrahydrobenzo[f]quinoline Chemical group C1=CC=CC2=C(CCCN3)C3=CC=C21 HRFUBWQYIAMTOD-UHFFFAOYSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical group CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- YWWZASFPWWPUBN-UHFFFAOYSA-N 1-bromoisoquinoline Chemical compound C1=CC=C2C(Br)=NC=CC2=C1 YWWZASFPWWPUBN-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical group CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- MJWBNIISXZJNDV-UHFFFAOYSA-N 2-(isoquinolin-1-ylamino)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound C1(=NC=CC2=CC=CC=C12)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC MJWBNIISXZJNDV-UHFFFAOYSA-N 0.000 description 1
- RBNFUEGAMTYXGT-UHFFFAOYSA-N 2-(pyrido[3,2-d]pyrimidin-4-ylamino)-4-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl-[2-(2,2,2-trifluoroethoxy)ethyl]amino]butanoic acid Chemical compound N1=CN=C(C2=C1C=CC=N2)NC(C(=O)O)CCN(CCOCC(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1 RBNFUEGAMTYXGT-UHFFFAOYSA-N 0.000 description 1
- ZVHVVZKZBSAJQM-UHFFFAOYSA-N 2-(quinazolin-4-ylamino)-4-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl-[2-(2,2,2-trifluoroethoxy)ethyl]amino]butanoic acid Chemical compound N1=CN=C(C2=CC=CC=C12)NC(C(=O)O)CCN(CCOCC(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1 ZVHVVZKZBSAJQM-UHFFFAOYSA-N 0.000 description 1
- UYMOSJMAWDJBMJ-UHFFFAOYSA-N 2-[(1-methylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-4-[2-methylsulfonylethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound CN1N=CC=2C1=NC=NC=2NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCS(=O)(=O)C UYMOSJMAWDJBMJ-UHFFFAOYSA-N 0.000 description 1
- FRQASQXVRLNQRN-UHFFFAOYSA-N 2-[(1-methylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-4-[2-phenoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound CN1N=CC=2C1=NC=NC=2NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC1=CC=CC=C1 FRQASQXVRLNQRN-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- LLDHSEZHUSEWDP-UHFFFAOYSA-N 2-[(3-cyanopyrazin-2-yl)amino]-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound C(#N)C=1C(=NC=CN=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC LLDHSEZHUSEWDP-UHFFFAOYSA-N 0.000 description 1
- ZGTFDWKUCGCCOR-UHFFFAOYSA-N 2-[(3-cyanopyrazin-2-yl)amino]-4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound C(#N)C=1C(=NC=CN=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(C)OC ZGTFDWKUCGCCOR-UHFFFAOYSA-N 0.000 description 1
- PVUNJFDGIRQSRE-UHFFFAOYSA-N 2-[(5-bromopyrimidin-2-yl)amino]-4-[(2-fluoro-3-methoxypropyl)-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound BrC=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(COC)F PVUNJFDGIRQSRE-UHFFFAOYSA-N 0.000 description 1
- OAPHNUIPPAFMCC-UHFFFAOYSA-N 2-[(5-bromopyrimidin-2-yl)amino]-4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound BrC=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(F)F OAPHNUIPPAFMCC-UHFFFAOYSA-N 0.000 description 1
- ISTYMXNQOZXIPN-UHFFFAOYSA-N 2-[(5-bromopyrimidin-2-yl)amino]-4-[2-(4-fluorophenoxy)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound BrC=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC1=CC=C(C=C1)F ISTYMXNQOZXIPN-UHFFFAOYSA-N 0.000 description 1
- RCWXXFPGMPXGJT-UHFFFAOYSA-N 2-[(5-bromopyrimidin-2-yl)amino]-4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound BrC=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(C)OC RCWXXFPGMPXGJT-UHFFFAOYSA-N 0.000 description 1
- KFPTUTBPAPCPKG-UHFFFAOYSA-N 2-[(5-bromopyrimidin-2-yl)amino]-4-[2-methylsulfonylethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound BrC=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCS(=O)(=O)C KFPTUTBPAPCPKG-UHFFFAOYSA-N 0.000 description 1
- CFNCACFTGRMXLK-UHFFFAOYSA-N 2-[(5-bromopyrimidin-2-yl)amino]-4-[2-phenoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound BrC=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC1=CC=CC=C1 CFNCACFTGRMXLK-UHFFFAOYSA-N 0.000 description 1
- MLVJCTIWVYAXRI-UHFFFAOYSA-N 2-[(5-bromopyrimidin-2-yl)amino]-4-[3,3-difluoropropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound BrC=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCC(F)F MLVJCTIWVYAXRI-UHFFFAOYSA-N 0.000 description 1
- UIUXPBJXTNSKSS-UHFFFAOYSA-N 2-[(5-cyanopyrimidin-2-yl)amino]-4-[(2-fluoro-3-methoxypropyl)-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound C(#N)C=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(COC)F UIUXPBJXTNSKSS-UHFFFAOYSA-N 0.000 description 1
- ZMPQYYQUMXERAI-UHFFFAOYSA-N 2-[(5-cyanopyrimidin-2-yl)amino]-4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound C(#N)C=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(F)F ZMPQYYQUMXERAI-UHFFFAOYSA-N 0.000 description 1
- OZSSSUOOQQMKPH-UHFFFAOYSA-N 2-[(5-cyanopyrimidin-2-yl)amino]-4-[2-(4-fluorophenoxy)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound C(#N)C=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC1=CC=C(C=C1)F OZSSSUOOQQMKPH-UHFFFAOYSA-N 0.000 description 1
- OMYWJDHKUOTHKT-UHFFFAOYSA-N 2-[(5-cyanopyrimidin-2-yl)amino]-4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound C(#N)C=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(C)OC OMYWJDHKUOTHKT-UHFFFAOYSA-N 0.000 description 1
- KGLKXFBEHNTXQA-UHFFFAOYSA-N 2-[(5-cyanopyrimidin-2-yl)amino]-4-[2-phenoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound C(#N)C=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC1=CC=CC=C1 KGLKXFBEHNTXQA-UHFFFAOYSA-N 0.000 description 1
- HRDIRQDRRJCNJC-UHFFFAOYSA-N 2-[(5-cyclopropylpyrimidin-2-yl)amino]-4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound C1(CC1)C=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(F)F HRDIRQDRRJCNJC-UHFFFAOYSA-N 0.000 description 1
- VGDLBRUTGYZVLA-UHFFFAOYSA-N 2-[(5-cyclopropylpyrimidin-2-yl)amino]-4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound C1(CC1)C=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(C)OC VGDLBRUTGYZVLA-UHFFFAOYSA-N 0.000 description 1
- MSOZXWRLSFBGRJ-UHFFFAOYSA-N 2-[(5-cyclopropylpyrimidin-2-yl)amino]-4-[2-phenoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound C1(CC1)C=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC1=CC=CC=C1 MSOZXWRLSFBGRJ-UHFFFAOYSA-N 0.000 description 1
- WRAPGMNNYFJAFF-UHFFFAOYSA-N 2-[(5-cyclopropylpyrimidin-2-yl)amino]-4-[3,3-difluoropropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound C1(CC1)C=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCC(F)F WRAPGMNNYFJAFF-UHFFFAOYSA-N 0.000 description 1
- HFRJIGSMLPAEPX-UHFFFAOYSA-N 2-[(5-fluoropyrimidin-2-yl)amino]-4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound FC=1C=NC(=NC=1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(C)OC HFRJIGSMLPAEPX-UHFFFAOYSA-N 0.000 description 1
- RVAMGWGBJBYJPF-UHFFFAOYSA-N 2-[(5-fluoroquinazolin-4-yl)amino]-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound COCCN(CCCCC1=CC=C2CCCNC2=N1)CCC(NC1=NC=NC2=CC=CC(F)=C12)C(O)=O RVAMGWGBJBYJPF-UHFFFAOYSA-N 0.000 description 1
- VSRHLQBJZGNGLG-UHFFFAOYSA-N 2-[(6,7-difluoroquinazolin-4-yl)amino]-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound FC=1C=C2C(=NC=NC2=CC=1F)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC VSRHLQBJZGNGLG-UHFFFAOYSA-N 0.000 description 1
- LVSNBVQEXTYLRP-UHFFFAOYSA-N 2-[(6-fluoroquinazolin-4-yl)amino]-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound COCCN(CCCCC1=CC=C2CCCNC2=N1)CCC(NC1=NC=NC2=CC=C(F)C=C12)C(O)=O LVSNBVQEXTYLRP-UHFFFAOYSA-N 0.000 description 1
- FRLFLFWXQJDPEU-UHFFFAOYSA-N 2-[(7-chloroquinazolin-4-yl)amino]-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound ClC1=CC=C2C(=NC=NC2=C1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC FRLFLFWXQJDPEU-UHFFFAOYSA-N 0.000 description 1
- NZTCSZHVEDAYAX-UHFFFAOYSA-N 2-[(7-fluoro-2-methylquinazolin-4-yl)amino]-4-[2-(2-methylpyridin-3-yl)oxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound FC1=CC=C2C(=NC(=NC2=C1)C)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC=1C(=NC=CC=1)C NZTCSZHVEDAYAX-UHFFFAOYSA-N 0.000 description 1
- WTPBTCDPVXXKAZ-UHFFFAOYSA-N 2-[(7-fluoro-2-methylquinazolin-4-yl)amino]-4-[2-(4-fluorophenoxy)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound FC1=CC=C2C(=NC(=NC2=C1)C)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC1=CC=C(C=C1)F WTPBTCDPVXXKAZ-UHFFFAOYSA-N 0.000 description 1
- UXAFLBSIOPJNAC-UHFFFAOYSA-N 2-[(7-fluoro-2-methylquinazolin-4-yl)amino]-4-[2-(5-fluoropyridin-3-yl)oxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound FC1=CC=C2C(=NC(=NC2=C1)C)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC=1C=NC=C(C=1)F UXAFLBSIOPJNAC-UHFFFAOYSA-N 0.000 description 1
- YSEJUMFQVIBKKC-UHFFFAOYSA-N 2-[(7-fluoro-2-methylquinazolin-4-yl)amino]-4-[2-(6-methylpyridin-3-yl)oxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound FC1=CC=C2C(=NC(=NC2=C1)C)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC=1C=NC(=CC=1)C YSEJUMFQVIBKKC-UHFFFAOYSA-N 0.000 description 1
- JIRFVZBHOYIAGH-UHFFFAOYSA-N 2-[(7-fluoro-2-methylquinazolin-4-yl)amino]-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound FC1=CC=C2C(=NC(=NC2=C1)C)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC JIRFVZBHOYIAGH-UHFFFAOYSA-N 0.000 description 1
- IOJXFJFHNHQUKS-UHFFFAOYSA-N 2-[(7-fluoro-2-methylquinazolin-4-yl)amino]-4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound FC1=CC=C2C(=NC(=NC2=C1)C)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(C)OC IOJXFJFHNHQUKS-UHFFFAOYSA-N 0.000 description 1
- SQXIAJNIFTZJMD-UHFFFAOYSA-N 2-[(7-fluoroquinazolin-4-yl)amino]-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound FC1=CC=C2C(=NC=NC2=C1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC SQXIAJNIFTZJMD-UHFFFAOYSA-N 0.000 description 1
- QHRASPFOEZEMQO-UHFFFAOYSA-N 2-[(8-chloroquinazolin-4-yl)amino]-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound ClC=1C=CC=C2C(=NC=NC=12)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC QHRASPFOEZEMQO-UHFFFAOYSA-N 0.000 description 1
- VRSJTCUXGCVOIQ-UHFFFAOYSA-N 2-[(8-chloroquinazolin-4-yl)amino]-4-[2-pyridin-2-yloxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound ClC=1C=CC=C2C(=NC=NC=12)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC1=NC=CC=C1 VRSJTCUXGCVOIQ-UHFFFAOYSA-N 0.000 description 1
- IIORPSLEOINQCI-UHFFFAOYSA-N 2-[(8-fluoroquinazolin-4-yl)amino]-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound COCCN(CCCCC1=CC=C2CCCNC2=N1)CCC(NC1=NC=NC2=C(F)C=CC=C12)C(O)=O IIORPSLEOINQCI-UHFFFAOYSA-N 0.000 description 1
- LUAINELMEBRPFK-UHFFFAOYSA-N 2-[[6-(difluoromethyl)pyrimidin-4-yl]amino]-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]butanoic acid Chemical compound FC(C1=CC(=NC=N1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC)F LUAINELMEBRPFK-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- APRMCBSTMFKLEI-UHFFFAOYSA-N 2-chloro-5-methylpyrimidine Chemical compound CC1=CN=C(Cl)N=C1 APRMCBSTMFKLEI-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- SDLFAEGTVBPHBK-UHFFFAOYSA-N 3-chloropyrazine-2-carbonitrile Chemical compound ClC1=NC=CN=C1C#N SDLFAEGTVBPHBK-UHFFFAOYSA-N 0.000 description 1
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 description 1
- AVAGDMNSAIAKBL-UHFFFAOYSA-N 4-[(2-fluoro-3-methoxypropyl)-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(pyrimidin-4-ylamino)butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC=NC=C1)CCCCC1=NC=2NCCCC=2C=C1)COC AVAGDMNSAIAKBL-UHFFFAOYSA-N 0.000 description 1
- VRLMGLDHARIMQT-UHFFFAOYSA-N 4-[(2-fluoro-3-methoxypropyl)-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1)COC VRLMGLDHARIMQT-UHFFFAOYSA-N 0.000 description 1
- KCCSLLNAHMZLNL-UHFFFAOYSA-N 4-[(2-fluoro-3-methoxypropyl)-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(1-methylpyrazolo[3,4-d]pyrimidin-4-yl)amino]butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=C2C(=NC=N1)N(N=C2)C)CCCCC1=NC=2NCCCC=2C=C1)COC KCCSLLNAHMZLNL-UHFFFAOYSA-N 0.000 description 1
- FOLYUFAELYQPOY-UHFFFAOYSA-N 4-[(2-fluoro-3-methoxypropyl)-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(2-pyridin-3-ylquinazolin-4-yl)amino]butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC(=NC2=CC=CC=C12)C=1C=NC=CC=1)CCCCC1=NC=2NCCCC=2C=C1)COC FOLYUFAELYQPOY-UHFFFAOYSA-N 0.000 description 1
- HOHZLIWKDPNIKN-UHFFFAOYSA-N 4-[(2-fluoro-3-methoxypropyl)-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(5-phenylpyrimidin-4-yl)amino]butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC=NC=C1C1=CC=CC=C1)CCCCC1=NC=2NCCCC=2C=C1)COC HOHZLIWKDPNIKN-UHFFFAOYSA-N 0.000 description 1
- HJVXRFQDVRJDQW-UHFFFAOYSA-N 4-[(2-fluoro-3-methoxypropyl)-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(6-phenylpyrimidin-4-yl)amino]butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC=NC(=C1)C1=CC=CC=C1)CCCCC1=NC=2NCCCC=2C=C1)COC HJVXRFQDVRJDQW-UHFFFAOYSA-N 0.000 description 1
- XEFVEBXAUPKHOO-UHFFFAOYSA-N 4-[(2-fluoro-3-methoxypropyl)-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(6-pyrazol-1-ylpyrimidin-4-yl)amino]butanoic acid Chemical compound N1(N=CC=C1)C1=CC(=NC=N1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(COC)F XEFVEBXAUPKHOO-UHFFFAOYSA-N 0.000 description 1
- BEWURCSISOTFOW-UHFFFAOYSA-N 4-[(2-fluoro-3-methoxypropyl)-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(7-fluoro-2-methylquinazolin-4-yl)amino]butanoic acid Chemical compound FC1=CC=C2C(=NC(=NC2=C1)C)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(COC)F BEWURCSISOTFOW-UHFFFAOYSA-N 0.000 description 1
- DRNAKEUEIWVLBV-UHFFFAOYSA-N 4-[(2-fluoro-3-methoxypropyl)-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[2-(trifluoromethyl)pyrimidin-4-yl]amino]butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC(=NC=C1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1)COC DRNAKEUEIWVLBV-UHFFFAOYSA-N 0.000 description 1
- VNECHKYIECIXLL-UHFFFAOYSA-N 4-[(2-fluoro-3-methoxypropyl)-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC=C(C=N1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1)COC VNECHKYIECIXLL-UHFFFAOYSA-N 0.000 description 1
- QELQEUKCMHKXAF-UHFFFAOYSA-N 4-[(2-hydroxy-2-methylpropyl)-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(pyrimidin-4-ylamino)butanoic acid Chemical compound OC(CN(CCC(C(=O)O)NC1=NC=NC=C1)CCCCC1=NC=2NCCCC=2C=C1)(C)C QELQEUKCMHKXAF-UHFFFAOYSA-N 0.000 description 1
- IEIQVKZZQPWGHH-UHFFFAOYSA-N 4-[(3,3-difluorocyclobutyl)-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound FC1(CC(C1)N(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1)F IEIQVKZZQPWGHH-UHFFFAOYSA-N 0.000 description 1
- KYYNIZNCJDAHBF-UHFFFAOYSA-N 4-[(3,3-difluorocyclobutyl)methyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(7-fluoro-2-methylquinazolin-4-yl)amino]butanoic acid Chemical compound FC1(CC(C1)CN(CCC(C(=O)O)NC1=NC(=NC2=CC(=CC=C12)F)C)CCCCC1=NC=2NCCCC=2C=C1)F KYYNIZNCJDAHBF-UHFFFAOYSA-N 0.000 description 1
- VVRXUTAYELKZGA-UHFFFAOYSA-N 4-[(3-fluorooxetan-3-yl)methyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound FC1(COC1)CN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 VVRXUTAYELKZGA-UHFFFAOYSA-N 0.000 description 1
- WFUKISJPCINNHD-UHFFFAOYSA-N 4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)butanoic acid Chemical compound N1N=CC=2C1=NC=NC=2NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(F)F WFUKISJPCINNHD-UHFFFAOYSA-N 0.000 description 1
- RNUPJBCFYHJZFJ-UHFFFAOYSA-N 4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(pyrimidin-4-ylamino)butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC=NC=C1)CCCCC1=NC=2NCCCC=2C=C1)F RNUPJBCFYHJZFJ-UHFFFAOYSA-N 0.000 description 1
- QLQWVDXKTCOBFF-UHFFFAOYSA-N 4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1)F QLQWVDXKTCOBFF-UHFFFAOYSA-N 0.000 description 1
- ZTODTVMWQKROBN-UHFFFAOYSA-N 4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(1-methylpyrazolo[3,4-d]pyrimidin-4-yl)amino]butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=C2C(=NC=N1)N(N=C2)C)CCCCC1=NC=2NCCCC=2C=C1)F ZTODTVMWQKROBN-UHFFFAOYSA-N 0.000 description 1
- PCZKSCFYEHCLNY-UHFFFAOYSA-N 4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(2-pyridin-3-ylquinazolin-4-yl)amino]butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC(=NC2=CC=CC=C12)C=1C=NC=CC=1)CCCCC1=NC=2NCCCC=2C=C1)F PCZKSCFYEHCLNY-UHFFFAOYSA-N 0.000 description 1
- PQDBEUQLCLWTCL-UHFFFAOYSA-N 4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(5-fluoropyrimidin-2-yl)amino]butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC=C(C=N1)F)CCCCC1=NC=2NCCCC=2C=C1)F PQDBEUQLCLWTCL-UHFFFAOYSA-N 0.000 description 1
- DYARWZMBGRSJFR-UHFFFAOYSA-N 4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(5-phenylpyrimidin-4-yl)amino]butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC=NC=C1C1=CC=CC=C1)CCCCC1=NC=2NCCCC=2C=C1)F DYARWZMBGRSJFR-UHFFFAOYSA-N 0.000 description 1
- XDXCCFXTQYSODJ-UHFFFAOYSA-N 4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(6-methyl-2-pyridin-4-ylpyrimidin-4-yl)amino]butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC(=NC(=C1)C)C1=CC=NC=C1)CCCCC1=NC=2NCCCC=2C=C1)F XDXCCFXTQYSODJ-UHFFFAOYSA-N 0.000 description 1
- BXXJFFAICZKXBP-UHFFFAOYSA-N 4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(6-phenylpyrimidin-4-yl)amino]butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC=NC(=C1)C1=CC=CC=C1)CCCCC1=NC=2NCCCC=2C=C1)F BXXJFFAICZKXBP-UHFFFAOYSA-N 0.000 description 1
- ZVYTXAZDYZPPRQ-UHFFFAOYSA-N 4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(6-pyrazol-1-ylpyrimidin-4-yl)amino]butanoic acid Chemical compound N1(N=CC=C1)C1=CC(=NC=N1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(F)F ZVYTXAZDYZPPRQ-UHFFFAOYSA-N 0.000 description 1
- DKRIZDMOEGJABV-UHFFFAOYSA-N 4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[2-(trifluoromethyl)pyrimidin-4-yl]amino]butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC(=NC=C1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1)F DKRIZDMOEGJABV-UHFFFAOYSA-N 0.000 description 1
- AUUCALBDLGCGEK-UHFFFAOYSA-N 4-[2,2-difluoroethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]butanoic acid Chemical compound FC(CN(CCC(C(=O)O)NC1=NC=C(C=N1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1)F AUUCALBDLGCGEK-UHFFFAOYSA-N 0.000 description 1
- TVGIBZQQUWICLR-UHFFFAOYSA-N 4-[2-(2,2-difluorocyclopropyl)oxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(7-fluoro-2-methylquinazolin-4-yl)amino]butanoic acid Chemical compound FC1(C(C1)OCCN(CCC(C(=O)O)NC1=NC(=NC2=CC(=CC=C12)F)C)CCCCC1=NC=2NCCCC=2C=C1)F TVGIBZQQUWICLR-UHFFFAOYSA-N 0.000 description 1
- HYBPIKZKVIIQLK-UHFFFAOYSA-N 4-[2-(2,2-difluoroethoxy)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound FC(COCCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1)F HYBPIKZKVIIQLK-UHFFFAOYSA-N 0.000 description 1
- QOLJFEZMOZJODB-UHFFFAOYSA-N 4-[2-(2-methylpyridin-3-yl)oxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(pyrido[3,2-d]pyrimidin-4-ylamino)butanoic acid Chemical compound CC1=NC=CC=C1OCCN(CCC(C(=O)O)NC=1C2=C(N=CN=1)C=CC=N2)CCCCC1=NC=2NCCCC=2C=C1 QOLJFEZMOZJODB-UHFFFAOYSA-N 0.000 description 1
- KCTCSJRKZCYUPW-UHFFFAOYSA-N 4-[2-(2-methylpyridin-3-yl)oxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound CC1=NC=CC=C1OCCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 KCTCSJRKZCYUPW-UHFFFAOYSA-N 0.000 description 1
- YWIXAKYDQQOJLI-UHFFFAOYSA-N 4-[2-(3,5-difluorophenoxy)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound FC=1C=C(OCCN(CCC(C(=O)O)NC2=NC=NC3=CC=CC=C23)CCCCC2=NC=3NCCCC=3C=C2)C=C(C=1)F YWIXAKYDQQOJLI-UHFFFAOYSA-N 0.000 description 1
- HWPUNNZLLODORJ-UHFFFAOYSA-N 4-[2-(3,5-dimethylpyrazol-1-yl)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound CC1=NN(C(=C1)C)CCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 HWPUNNZLLODORJ-UHFFFAOYSA-N 0.000 description 1
- NYIJVOPSVVFNKF-UHFFFAOYSA-N 4-[2-(4-fluorophenoxy)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)butanoic acid Chemical compound N1N=CC=2C1=NC=NC=2NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC1=CC=C(C=C1)F NYIJVOPSVVFNKF-UHFFFAOYSA-N 0.000 description 1
- GDXGYBFRXVJQDK-UHFFFAOYSA-N 4-[2-(4-fluorophenoxy)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(1-methylpyrazolo[3,4-d]pyrimidin-4-yl)amino]butanoic acid Chemical compound FC1=CC=C(OCCN(CCC(C(=O)O)NC2=C3C(=NC=N2)N(N=C3)C)CCCCC2=NC=3NCCCC=3C=C2)C=C1 GDXGYBFRXVJQDK-UHFFFAOYSA-N 0.000 description 1
- YIECNNGRAZAQBT-UHFFFAOYSA-N 4-[2-(4-fluorophenoxy)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]butanoic acid Chemical compound FC1=CC=C(OCCN(CCC(C(=O)O)NC2=NC=C(C=N2)C(F)(F)F)CCCCC2=NC=3NCCCC=3C=C2)C=C1 YIECNNGRAZAQBT-UHFFFAOYSA-N 0.000 description 1
- TUOYFCDKLKOBCE-UHFFFAOYSA-N 4-[2-(5-fluoropyridin-3-yl)oxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(pyrido[3,2-d]pyrimidin-4-ylamino)butanoic acid Chemical compound FC=1C=C(C=NC=1)OCCN(CCC(C(=O)O)NC=1C2=C(N=CN=1)C=CC=N2)CCCCC1=NC=2NCCCC=2C=C1 TUOYFCDKLKOBCE-UHFFFAOYSA-N 0.000 description 1
- QJSANTJBXMXHDL-UHFFFAOYSA-N 4-[2-(5-fluoropyridin-3-yl)oxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound FC=1C=C(C=NC=1)OCCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 QJSANTJBXMXHDL-UHFFFAOYSA-N 0.000 description 1
- QIXKNSAILWAQDK-UHFFFAOYSA-N 4-[2-(6-methylpyridin-3-yl)oxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(pyrido[3,2-d]pyrimidin-4-ylamino)butanoic acid Chemical compound CC1=CC=C(C=N1)OCCN(CCC(C(=O)O)NC=1C2=C(N=CN=1)C=CC=N2)CCCCC1=NC=2NCCCC=2C=C1 QIXKNSAILWAQDK-UHFFFAOYSA-N 0.000 description 1
- CFPUBPURYNXJHK-UHFFFAOYSA-N 4-[2-(6-methylpyridin-3-yl)oxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound CC1=CC=C(C=N1)OCCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 CFPUBPURYNXJHK-UHFFFAOYSA-N 0.000 description 1
- BJNKQNQGPXTMHF-UHFFFAOYSA-N 4-[2-(difluoromethoxy)ethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound FC(OCCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1)F BJNKQNQGPXTMHF-UHFFFAOYSA-N 0.000 description 1
- VSMVYEGXRFEPTM-UHFFFAOYSA-N 4-[2-acetamidoethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound C(C)(=O)NCCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 VSMVYEGXRFEPTM-UHFFFAOYSA-N 0.000 description 1
- NYYANOTUBQGCKV-UHFFFAOYSA-N 4-[2-ethoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound C(C)OCCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 NYYANOTUBQGCKV-UHFFFAOYSA-N 0.000 description 1
- ZOONEWNJDYOTCN-UHFFFAOYSA-N 4-[2-hydroxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound OCCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 ZOONEWNJDYOTCN-UHFFFAOYSA-N 0.000 description 1
- FXEXRGIVOAFXCR-UHFFFAOYSA-N 4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(pyrido[2,3-d]pyrimidin-4-ylamino)butanoic acid Chemical compound COCCN(CCC(C(=O)O)NC=1C2=C(N=CN=1)N=CC=C2)CCCCC1=NC=2NCCCC=2C=C1 FXEXRGIVOAFXCR-UHFFFAOYSA-N 0.000 description 1
- SUVFZKPMSXIDLY-UHFFFAOYSA-N 4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(pyrido[3,2-d]pyrimidin-4-ylamino)butanoic acid Chemical compound COCCN(CCC(C(=O)O)NC=1C2=C(N=CN=1)C=CC=N2)CCCCC1=NC=2NCCCC=2C=C1 SUVFZKPMSXIDLY-UHFFFAOYSA-N 0.000 description 1
- YDAPEUXGKKAJBC-UHFFFAOYSA-N 4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(pyrido[3,4-d]pyrimidin-4-ylamino)butanoic acid Chemical compound COCCN(CCC(C(=O)O)NC=1C2=C(N=CN=1)C=NC=C2)CCCCC1=NC=2NCCCC=2C=C1 YDAPEUXGKKAJBC-UHFFFAOYSA-N 0.000 description 1
- CWOFQJBATWQSHL-UHFFFAOYSA-N 4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound COCCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 CWOFQJBATWQSHL-UHFFFAOYSA-N 0.000 description 1
- JEWMTYWBYMTNPA-UHFFFAOYSA-N 4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinolin-4-ylamino)butanoic acid Chemical compound COCCN(CCC(C(=O)O)NC1=CC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 JEWMTYWBYMTNPA-UHFFFAOYSA-N 0.000 description 1
- AXGBIWKTVNAQDZ-UHFFFAOYSA-N 4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(2-methylquinazolin-4-yl)amino]butanoic acid Chemical compound COCCN(CCC(C(=O)O)NC1=NC(=NC2=CC=CC=C12)C)CCCCC1=NC=2NCCCC=2C=C1 AXGBIWKTVNAQDZ-UHFFFAOYSA-N 0.000 description 1
- MKSZPWOPXXEADG-UHFFFAOYSA-N 4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(6-pyrazol-1-ylpyrimidin-4-yl)amino]butanoic acid Chemical compound N1(N=CC=C1)C1=CC(=NC=N1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC MKSZPWOPXXEADG-UHFFFAOYSA-N 0.000 description 1
- DRPFMHBSKICVQX-UHFFFAOYSA-N 4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[2-(trifluoromethyl)pyrimidin-4-yl]amino]butanoic acid Chemical compound COCCN(CCC(C(=O)O)NC1=NC(=NC=C1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1 DRPFMHBSKICVQX-UHFFFAOYSA-N 0.000 description 1
- OOPWGIOHLDTPLQ-UHFFFAOYSA-N 4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[2-(trifluoromethyl)quinazolin-4-yl]amino]butanoic acid Chemical compound COCCN(CCC(C(=O)O)NC1=NC(=NC2=CC=CC=C12)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1 OOPWGIOHLDTPLQ-UHFFFAOYSA-N 0.000 description 1
- TWSTXCPMBSZKRI-UHFFFAOYSA-N 4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[2-methyl-6-(trifluoromethyl)pyrimidin-4-yl]amino]butanoic acid Chemical compound COCCN(CCC(C(=O)O)NC1=NC(=NC(=C1)C(F)(F)F)C)CCCCC1=NC=2NCCCC=2C=C1 TWSTXCPMBSZKRI-UHFFFAOYSA-N 0.000 description 1
- NMGFFGGKHUGVHL-UHFFFAOYSA-N 4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[6-methyl-2-(trifluoromethyl)pyrimidin-4-yl]amino]butanoic acid Chemical compound COCCN(CCC(C(=O)O)NC1=NC(=NC(=C1)C)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1 NMGFFGGKHUGVHL-UHFFFAOYSA-N 0.000 description 1
- ITUSCLRGOZYBSW-UHFFFAOYSA-N 4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[7-(trifluoromethyl)quinazolin-4-yl]amino]butanoic acid Chemical compound COCCN(CCC(C(=O)O)NC1=NC=NC2=CC(=CC=C12)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1 ITUSCLRGOZYBSW-UHFFFAOYSA-N 0.000 description 1
- SWDNHTGWYLWWNQ-UHFFFAOYSA-N 4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[8-(trifluoromethyl)quinazolin-4-yl]amino]butanoic acid Chemical compound COCCN(CCC(C(=O)O)NC1=NC=NC2=C(C=CC=C12)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1 SWDNHTGWYLWWNQ-UHFFFAOYSA-N 0.000 description 1
- BMUQTOFZSKNIQX-UHFFFAOYSA-N 4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)butanoic acid Chemical compound N1N=CC=2C1=NC=NC=2NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(C)OC BMUQTOFZSKNIQX-UHFFFAOYSA-N 0.000 description 1
- NGVLIKXQIPCVQZ-UHFFFAOYSA-N 4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(1H-pyrazolo[4,3-d]pyrimidin-7-ylamino)butanoic acid Chemical compound N1N=CC=2N=CN=C(C=21)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(C)OC NGVLIKXQIPCVQZ-UHFFFAOYSA-N 0.000 description 1
- MSFNENYYBSZXCJ-UHFFFAOYSA-N 4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(pyrimidin-4-ylamino)butanoic acid Chemical compound COC(CN(CCC(C(=O)O)NC1=NC=NC=C1)CCCCC1=NC=2NCCCC=2C=C1)C MSFNENYYBSZXCJ-UHFFFAOYSA-N 0.000 description 1
- QUIVJQHNUZXPEF-UHFFFAOYSA-N 4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound COC(CN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1)C QUIVJQHNUZXPEF-UHFFFAOYSA-N 0.000 description 1
- CFTPRRDFVCAKOU-UHFFFAOYSA-N 4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(1-methylpyrazolo[3,4-d]pyrimidin-4-yl)amino]butanoic acid Chemical compound COC(CN(CCC(C(=O)O)NC1=C2C(=NC=N1)N(N=C2)C)CCCCC1=NC=2NCCCC=2C=C1)C CFTPRRDFVCAKOU-UHFFFAOYSA-N 0.000 description 1
- XNPVHPTYLQPOLE-UHFFFAOYSA-N 4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(2-methylquinazolin-4-yl)amino]butanoic acid Chemical compound COC(CN(CCC(C(=O)O)NC1=NC(=NC2=CC=CC=C12)C)CCCCC1=NC=2NCCCC=2C=C1)C XNPVHPTYLQPOLE-UHFFFAOYSA-N 0.000 description 1
- IFLPSVYBZXWZIT-UHFFFAOYSA-N 4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(2-phenylpyrimidin-4-yl)amino]butanoic acid Chemical compound COC(CN(CCC(C(=O)O)NC1=NC(=NC=C1)C1=CC=CC=C1)CCCCC1=NC=2NCCCC=2C=C1)C IFLPSVYBZXWZIT-UHFFFAOYSA-N 0.000 description 1
- HDOQYSVAWYXQTM-UHFFFAOYSA-N 4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(2-pyridin-3-ylquinazolin-4-yl)amino]butanoic acid Chemical compound COC(CN(CCC(C(=O)O)NC1=NC(=NC2=CC=CC=C12)C=1C=NC=CC=1)CCCCC1=NC=2NCCCC=2C=C1)C HDOQYSVAWYXQTM-UHFFFAOYSA-N 0.000 description 1
- ACJLQYXHEAZYTA-UHFFFAOYSA-N 4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(5-phenylpyrimidin-4-yl)amino]butanoic acid Chemical compound COC(CN(CCC(C(=O)O)NC1=NC=NC=C1C1=CC=CC=C1)CCCCC1=NC=2NCCCC=2C=C1)C ACJLQYXHEAZYTA-UHFFFAOYSA-N 0.000 description 1
- HIZITVFBHOPCCQ-UHFFFAOYSA-N 4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(6-phenylpyrimidin-4-yl)amino]butanoic acid Chemical compound COC(CN(CCC(C(=O)O)NC1=NC=NC(=C1)C1=CC=CC=C1)CCCCC1=NC=2NCCCC=2C=C1)C HIZITVFBHOPCCQ-UHFFFAOYSA-N 0.000 description 1
- LAHWKYVUGMIDAF-UHFFFAOYSA-N 4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(6-pyrazol-1-ylpyrimidin-4-yl)amino]butanoic acid Chemical compound N1(N=CC=C1)C1=CC(=NC=N1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CC(C)OC LAHWKYVUGMIDAF-UHFFFAOYSA-N 0.000 description 1
- KPCVTZQMIDGDSD-UHFFFAOYSA-N 4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[2-(trifluoromethyl)pyrimidin-4-yl]amino]butanoic acid Chemical compound COC(CN(CCC(C(=O)O)NC1=NC(=NC=C1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1)C KPCVTZQMIDGDSD-UHFFFAOYSA-N 0.000 description 1
- RJYAYMXOZISIMT-UHFFFAOYSA-N 4-[2-methoxypropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]butanoic acid Chemical compound COC(CN(CCC(C(=O)O)NC1=NC=C(C=N1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1)C RJYAYMXOZISIMT-UHFFFAOYSA-N 0.000 description 1
- GVGUPQRRZKSMPE-UHFFFAOYSA-N 4-[2-methylsulfonylethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)butanoic acid Chemical compound N1N=CC=2C1=NC=NC=2NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCS(=O)(=O)C GVGUPQRRZKSMPE-UHFFFAOYSA-N 0.000 description 1
- WCGAGWLWOQYESO-UHFFFAOYSA-N 4-[2-methylsulfonylethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound CS(=O)(=O)CCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 WCGAGWLWOQYESO-UHFFFAOYSA-N 0.000 description 1
- RSXKUDHUICLXQJ-UHFFFAOYSA-N 4-[2-methylsulfonylethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(2-pyridin-3-ylquinazolin-4-yl)amino]butanoic acid Chemical compound CS(=O)(=O)CCN(CCC(C(=O)O)NC1=NC(=NC2=CC=CC=C12)C=1C=NC=CC=1)CCCCC1=NC=2NCCCC=2C=C1 RSXKUDHUICLXQJ-UHFFFAOYSA-N 0.000 description 1
- CBABINZKYHSJHZ-UHFFFAOYSA-N 4-[2-methylsulfonylethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(6-pyrazol-1-ylpyrimidin-4-yl)amino]butanoic acid Chemical compound N1(N=CC=C1)C1=CC(=NC=N1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCS(=O)(=O)C CBABINZKYHSJHZ-UHFFFAOYSA-N 0.000 description 1
- ZHMQCWHLRQXPLO-UHFFFAOYSA-N 4-[2-methylsulfonylethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[2-(trifluoromethyl)pyrimidin-4-yl]amino]butanoic acid Chemical compound CS(=O)(=O)CCN(CCC(C(=O)O)NC1=NC(=NC=C1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1 ZHMQCWHLRQXPLO-UHFFFAOYSA-N 0.000 description 1
- HGEVCYIOJBUBPN-UHFFFAOYSA-N 4-[2-methylsulfonylethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]butanoic acid Chemical compound CS(=O)(=O)CCN(CCC(C(=O)O)NC1=NC=C(C=N1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1 HGEVCYIOJBUBPN-UHFFFAOYSA-N 0.000 description 1
- CNBMGCINRUYBSL-UHFFFAOYSA-N 4-[2-phenoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)butanoic acid Chemical compound N1N=CC=2C1=NC=NC=2NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC1=CC=CC=C1 CNBMGCINRUYBSL-UHFFFAOYSA-N 0.000 description 1
- TYSLZWIAOWCPIS-UHFFFAOYSA-N 4-[2-phenoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound O(C1=CC=CC=C1)CCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 TYSLZWIAOWCPIS-UHFFFAOYSA-N 0.000 description 1
- AMPZKKWXKWZGQO-UHFFFAOYSA-N 4-[2-phenoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(2-pyridin-3-ylquinazolin-4-yl)amino]butanoic acid Chemical compound O(C1=CC=CC=C1)CCN(CCC(C(=O)O)NC1=NC(=NC2=CC=CC=C12)C=1C=NC=CC=1)CCCCC1=NC=2NCCCC=2C=C1 AMPZKKWXKWZGQO-UHFFFAOYSA-N 0.000 description 1
- XGFDNCINTPJMBL-UHFFFAOYSA-N 4-[2-phenoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(6-phenylpyrimidin-4-yl)amino]butanoic acid Chemical compound O(C1=CC=CC=C1)CCN(CCC(C(=O)O)NC1=NC=NC(=C1)C1=CC=CC=C1)CCCCC1=NC=2NCCCC=2C=C1 XGFDNCINTPJMBL-UHFFFAOYSA-N 0.000 description 1
- QHFUDAPTPFSBBX-UHFFFAOYSA-N 4-[2-phenoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(6-pyrazol-1-ylpyrimidin-4-yl)amino]butanoic acid Chemical compound N1(N=CC=C1)C1=CC(=NC=N1)NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)CCOC1=CC=CC=C1 QHFUDAPTPFSBBX-UHFFFAOYSA-N 0.000 description 1
- BJXDZMMLRLXKIE-UHFFFAOYSA-N 4-[2-phenoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[2-(trifluoromethyl)pyrimidin-4-yl]amino]butanoic acid Chemical compound O(C1=CC=CC=C1)CCN(CCC(C(=O)O)NC1=NC(=NC=C1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1 BJXDZMMLRLXKIE-UHFFFAOYSA-N 0.000 description 1
- FLQSXLCACLDDAH-UHFFFAOYSA-N 4-[2-phenoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]butanoic acid Chemical compound O(C1=CC=CC=C1)CCN(CCC(C(=O)O)NC1=NC=C(C=N1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1 FLQSXLCACLDDAH-UHFFFAOYSA-N 0.000 description 1
- ZMYPVKYGPRYSTI-UHFFFAOYSA-N 4-[2-pyridin-2-yloxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound N1=C(C=CC=C1)OCCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 ZMYPVKYGPRYSTI-UHFFFAOYSA-N 0.000 description 1
- OQLXZXKGQYXCIG-UHFFFAOYSA-N 4-[3,3-difluoropropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound FC(CCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1)F OQLXZXKGQYXCIG-UHFFFAOYSA-N 0.000 description 1
- SXHBIHNIKMXDBA-UHFFFAOYSA-N 4-[3,3-difluoropropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(1-methylpyrazolo[3,4-d]pyrimidin-4-yl)amino]butanoic acid Chemical compound FC(CCN(CCC(C(=O)O)NC1=C2C(=NC=N1)N(N=C2)C)CCCCC1=NC=2NCCCC=2C=C1)F SXHBIHNIKMXDBA-UHFFFAOYSA-N 0.000 description 1
- OLYGJMIIGKIKIG-UHFFFAOYSA-N 4-[3,3-difluoropropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[2-(trifluoromethyl)pyrimidin-4-yl]amino]butanoic acid Chemical compound FC(CCN(CCC(C(=O)O)NC1=NC(=NC=C1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1)F OLYGJMIIGKIKIG-UHFFFAOYSA-N 0.000 description 1
- VWJRHICPKCXJIR-UHFFFAOYSA-N 4-[3,3-difluoropropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]butanoic acid Chemical compound FC(CCN(CCC(C(=O)O)NC1=NC=C(C=N1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1)F VWJRHICPKCXJIR-UHFFFAOYSA-N 0.000 description 1
- WTXPSZFZSMBHDG-UHFFFAOYSA-N 4-[3-fluoropropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound FCCCN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 WTXPSZFZSMBHDG-UHFFFAOYSA-N 0.000 description 1
- UTGNEYJLNPDIER-UHFFFAOYSA-N 4-[3-fluoropropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(1-methylpyrazolo[3,4-d]pyrimidin-4-yl)amino]butanoic acid Chemical compound FCCCN(CCC(C(=O)O)NC1=C2C(=NC=N1)N(N=C2)C)CCCCC1=NC=2NCCCC=2C=C1 UTGNEYJLNPDIER-UHFFFAOYSA-N 0.000 description 1
- PHHOCUOBAZKXBS-UHFFFAOYSA-N 4-[3-fluoropropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(7-methoxyquinazolin-4-yl)amino]butanoic acid Chemical compound FCCCN(CCC(C(=O)O)NC1=NC=NC2=CC(=CC=C12)OC)CCCCC1=NC=2NCCCC=2C=C1 PHHOCUOBAZKXBS-UHFFFAOYSA-N 0.000 description 1
- KUYYRCBRMCAUCS-UHFFFAOYSA-N 4-[3-fluoropropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(8-methoxyquinazolin-4-yl)amino]butanoic acid Chemical compound FCCCN(CCC(C(=O)O)NC1=NC=NC2=C(C=CC=C12)OC)CCCCC1=NC=2NCCCC=2C=C1 KUYYRCBRMCAUCS-UHFFFAOYSA-N 0.000 description 1
- YPNSPVVIDFWJJM-UHFFFAOYSA-N 4-[3-fluoropropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]butanoic acid Chemical compound FCCCN(CCC(C(=O)O)NC1=NC=C(C=N1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1 YPNSPVVIDFWJJM-UHFFFAOYSA-N 0.000 description 1
- QUIVJQHNUZXPEF-VGOKPJQXSA-N 4-[[(2R)-2-methoxypropyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound CO[C@@H](CN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1)C QUIVJQHNUZXPEF-VGOKPJQXSA-N 0.000 description 1
- IUWCJBLRXIAUAG-CHQVSRGASA-N 4-[[(2S)-2-fluoro-3-methoxypropyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(2-methylquinazolin-4-yl)amino]butanoic acid Chemical compound F[C@@H](CN(CCC(C(=O)O)NC1=NC(=NC2=CC=CC=C12)C)CCCCC1=NC=2NCCCC=2C=C1)COC IUWCJBLRXIAUAG-CHQVSRGASA-N 0.000 description 1
- FZADLLFHPKOTSF-UHFFFAOYSA-N 4-[[2-(dimethylamino)-2-oxoethyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound CN(C(CN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1)=O)C FZADLLFHPKOTSF-UHFFFAOYSA-N 0.000 description 1
- WRFIXPUWVYCVEA-UHFFFAOYSA-N 4-[[2-(dimethylamino)-2-oxoethyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(1-methylpyrazolo[3,4-d]pyrimidin-4-yl)amino]butanoic acid Chemical compound CN(C(CN(CCC(C(=O)O)NC1=C2C(=NC=N1)N(N=C2)C)CCCCC1=NC=2NCCCC=2C=C1)=O)C WRFIXPUWVYCVEA-UHFFFAOYSA-N 0.000 description 1
- CVYGSDQSQKUUJT-UHFFFAOYSA-N 4-[[2-(dimethylamino)-2-oxoethyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[2-(trifluoromethyl)pyrimidin-4-yl]amino]butanoic acid Chemical compound CN(C(CN(CCC(C(=O)O)NC1=NC(=NC=C1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1)=O)C CVYGSDQSQKUUJT-UHFFFAOYSA-N 0.000 description 1
- LGXRBPOHXLBIKM-UHFFFAOYSA-N 4-[[2-(dimethylamino)-2-oxoethyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]butanoic acid Chemical compound CN(C(CN(CCC(C(=O)O)NC1=NC=C(C=N1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1)=O)C LGXRBPOHXLBIKM-UHFFFAOYSA-N 0.000 description 1
- YLUVEYMCZFZKTR-UHFFFAOYSA-N 4-[[3-hydroxy-2-(hydroxymethyl)propyl]-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound OCC(CN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1)CO YLUVEYMCZFZKTR-UHFFFAOYSA-N 0.000 description 1
- JXMJWKSIBSTJIF-UHFFFAOYSA-N 4-[cyclopropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)butanoic acid Chemical compound N1N=CC=2C1=NC=NC=2NC(C(=O)O)CCN(CCCCC1=NC=2NCCCC=2C=C1)C1CC1 JXMJWKSIBSTJIF-UHFFFAOYSA-N 0.000 description 1
- ZHVJYOAURCOISG-UHFFFAOYSA-N 4-[cyclopropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(pyrimidin-4-ylamino)butanoic acid Chemical compound C1(CC1)N(CCC(C(=O)O)NC1=NC=NC=C1)CCCCC1=NC=2NCCCC=2C=C1 ZHVJYOAURCOISG-UHFFFAOYSA-N 0.000 description 1
- ZSMGYPDQBQVUFI-UHFFFAOYSA-N 4-[cyclopropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound C1(CC1)N(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 ZSMGYPDQBQVUFI-UHFFFAOYSA-N 0.000 description 1
- BZIPVKZSYWELMQ-UHFFFAOYSA-N 4-[cyclopropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(1-methylpyrazolo[3,4-d]pyrimidin-4-yl)amino]butanoic acid Chemical compound C1(CC1)N(CCC(C(=O)O)NC1=C2C(=NC=N1)N(N=C2)C)CCCCC1=NC=2NCCCC=2C=C1 BZIPVKZSYWELMQ-UHFFFAOYSA-N 0.000 description 1
- YELAOQDTELRPSE-UHFFFAOYSA-N 4-[cyclopropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[2-(trifluoromethyl)pyrimidin-4-yl]amino]butanoic acid Chemical compound C1(CC1)N(CCC(C(=O)O)NC1=NC(=NC=C1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1 YELAOQDTELRPSE-UHFFFAOYSA-N 0.000 description 1
- QCFNRAGUMKJHAV-UHFFFAOYSA-N 4-[cyclopropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[5-(trifluoromethyl)pyrimidin-2-yl]amino]butanoic acid Chemical compound C1(CC1)N(CCC(C(=O)O)NC1=NC=C(C=N1)C(F)(F)F)CCCCC1=NC=2NCCCC=2C=C1 QCFNRAGUMKJHAV-UHFFFAOYSA-N 0.000 description 1
- PNKBWMFDXVFJCQ-UHFFFAOYSA-N 4-[cyclopropyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[[6-(difluoromethyl)pyrimidin-4-yl]amino]butanoic acid Chemical compound C1(CC1)N(CCC(C(=O)O)NC1=NC=NC(=C1)C(F)F)CCCCC1=NC=2NCCCC=2C=C1 PNKBWMFDXVFJCQ-UHFFFAOYSA-N 0.000 description 1
- RAESYELMNRZAGH-UHFFFAOYSA-N 4-[oxetan-2-ylmethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound O1C(CC1)CN(CCC(C(=O)O)NC1=NC=NC2=CC=CC=C12)CCCCC1=NC=2NCCCC=2C=C1 RAESYELMNRZAGH-UHFFFAOYSA-N 0.000 description 1
- SUXIPCHEUMEUSV-UHFFFAOYSA-N 4-bromoquinoline Chemical compound C1=CC=C2C(Br)=CC=NC2=C1 SUXIPCHEUMEUSV-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010053487 Exposure to toxic agent Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000713297 Influenza C virus Species 0.000 description 1
- 241000401051 Influenza D virus Species 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 101800001155 Latency-associated peptide Proteins 0.000 description 1
- 102400000401 Latency-associated peptide Human genes 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 101100012902 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FIG2 gene Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000005724 cycloalkenylene group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004977 cycloheptylene group Chemical group 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940125436 dual inhibitor Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- IRKIQOVRUNZTED-UHFFFAOYSA-N ethyl 4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butanoate Chemical compound C1CCNC2=NC(CCCC(=O)OCC)=CC=C21 IRKIQOVRUNZTED-UHFFFAOYSA-N 0.000 description 1
- OUHHAOKXQRZRSY-UHFFFAOYSA-N ethyl 6-oxoheptanoate Chemical compound CCOC(=O)CCCCC(C)=O OUHHAOKXQRZRSY-UHFFFAOYSA-N 0.000 description 1
- IJIXKXZGLVMEDN-UHFFFAOYSA-N ethyl 7-oxooctanoate Chemical compound CCOC(=O)CCCCCC(C)=O IJIXKXZGLVMEDN-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000019589 hardness Nutrition 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004254 isoquinolin-1-yl group Chemical group [H]C1=C([H])C2=C([H])C([H])=C([H])C([H])=C2C(*)=N1 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- NDBQJIBNNUJNHA-AENDTGMFSA-N methyl (2r)-2-amino-3-hydroxypropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](N)CO NDBQJIBNNUJNHA-AENDTGMFSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000006209 tert-butylation Effects 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063021674P | 2020-05-07 | 2020-05-07 | |
| US63/021,674 | 2020-05-07 | ||
| PCT/US2021/030363 WO2021225912A1 (en) | 2020-05-07 | 2021-04-30 | Treatment of respiratory diseases with amino acid compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115989235A true CN115989235A (zh) | 2023-04-18 |
Family
ID=78468277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180048580.XA Withdrawn CN115989235A (zh) | 2020-05-07 | 2021-04-30 | 使用氨基酸化合物治疗呼吸系统疾病的方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181546A1 (enExample) |
| EP (2) | EP4520329A3 (enExample) |
| JP (1) | JP2023524970A (enExample) |
| KR (1) | KR20230049584A (enExample) |
| CN (1) | CN115989235A (enExample) |
| AU (1) | AU2021268889A1 (enExample) |
| CA (1) | CA3173761A1 (enExample) |
| IL (1) | IL297969A (enExample) |
| MX (1) | MX2022013753A (enExample) |
| WO (1) | WO2021225912A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024235299A1 (zh) * | 2023-05-17 | 2024-11-21 | 西藏海思科制药有限公司 | 一种羧基衍生物及其在医药上的应用 |
| WO2025067384A1 (zh) * | 2023-09-28 | 2025-04-03 | 成都微芯药业有限公司 | 一类氨基酸整联蛋白抑制剂、其制备方法及其应用 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| TW202235417A (zh) * | 2020-11-19 | 2022-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| US20230028658A1 (en) * | 2021-04-30 | 2023-01-26 | Pliant Therapeutics, Inc. | Expanded dosage regimens for integrin inhibitors |
| US20240122930A1 (en) * | 2022-07-09 | 2024-04-18 | Pliant Therapeutics, Inc. | Integrin inhibitors and uses thereof in combination with other agents |
| EP4626878A1 (en) | 2022-12-02 | 2025-10-08 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
| WO2024125634A1 (zh) * | 2022-12-16 | 2024-06-20 | 西藏海思科制药有限公司 | 一种四氢萘啶类化合物及其在医药上的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ502546A (en) * | 1997-08-08 | 2002-02-01 | Univ California | Treatment of acute lung injury and fibrosis with antibodies to alpha-v-beta-6 |
| DE10204789A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta6 |
| EP3925959A1 (en) * | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| JP2018514568A (ja) * | 2015-04-30 | 2018-06-07 | サイフルーア ライフ サイエンシズ インコーポレイテッド | テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法 |
| US10118929B2 (en) * | 2016-04-27 | 2018-11-06 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| WO2018183795A1 (en) * | 2017-03-30 | 2018-10-04 | Scifluor Life Sciences, Inc. | Method of making tetrahydronaphthyridinyl nonanoic acid compounds |
| CU24684B1 (es) * | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| MX2021004173A (es) * | 2018-10-09 | 2021-09-08 | Medimmune Llc | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. |
-
2021
- 2021-04-30 KR KR1020227042773A patent/KR20230049584A/ko active Pending
- 2021-04-30 MX MX2022013753A patent/MX2022013753A/es unknown
- 2021-04-30 WO PCT/US2021/030363 patent/WO2021225912A1/en not_active Ceased
- 2021-04-30 CN CN202180048580.XA patent/CN115989235A/zh not_active Withdrawn
- 2021-04-30 EP EP25152378.3A patent/EP4520329A3/en not_active Ceased
- 2021-04-30 JP JP2022567249A patent/JP2023524970A/ja not_active Withdrawn
- 2021-04-30 CA CA3173761A patent/CA3173761A1/en active Pending
- 2021-04-30 AU AU2021268889A patent/AU2021268889A1/en not_active Abandoned
- 2021-04-30 EP EP21799675.0A patent/EP4146264A4/en not_active Withdrawn
- 2021-04-30 US US17/923,899 patent/US20230181546A1/en not_active Abandoned
- 2021-04-30 IL IL297969A patent/IL297969A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024235299A1 (zh) * | 2023-05-17 | 2024-11-21 | 西藏海思科制药有限公司 | 一种羧基衍生物及其在医药上的应用 |
| WO2025067384A1 (zh) * | 2023-09-28 | 2025-04-03 | 成都微芯药业有限公司 | 一类氨基酸整联蛋白抑制剂、其制备方法及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021268889A1 (en) | 2022-12-15 |
| MX2022013753A (es) | 2023-01-30 |
| JP2023524970A (ja) | 2023-06-14 |
| CA3173761A1 (en) | 2021-11-11 |
| EP4520329A2 (en) | 2025-03-12 |
| EP4146264A4 (en) | 2024-07-24 |
| EP4146264A1 (en) | 2023-03-15 |
| IL297969A (en) | 2023-01-01 |
| KR20230049584A (ko) | 2023-04-13 |
| US20230181546A1 (en) | 2023-06-15 |
| EP4520329A3 (en) | 2025-05-14 |
| WO2021225912A1 (en) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI892960B (zh) | 胺基酸化合物及使用方法 | |
| US12390463B2 (en) | Dosage forms and regimens for amino acid compounds | |
| EP4520329A2 (en) | Treatment of respiratory diseases with amino acid compounds | |
| KR20240024060A (ko) | 인테그린 억제제에 대한 확장된 투여량 요법 | |
| HK40092721A (en) | Methods for treating respiratory diseases with amino acid compounds | |
| HK40070149A (en) | Dosage forms and regimens for amino acid compounds | |
| HK40044282A (en) | Amino acid compounds and methods of use | |
| KR20240136406A (ko) | 신규한 cdk9 억제제 | |
| BR122024019819A2 (pt) | Compostos de aminoácidos, seus usos e composição farmacêutica dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40092721 Country of ref document: HK |
|
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20230418 |
|
| WW01 | Invention patent application withdrawn after publication |